These patients have higher complement mutation frequency, including rare germline mutations in the alternative CS pathway (CFHR1, CFHR3, CFI, CFB, and CD46) than women with preeclampsia, having similar rates of variants as the control population (438, 439). This evidence concerns the gene CFI and preeclampsia.